Last Updated: 2026-03-28 PT
This knowledge gap addresses one of the most fundamental questions in Frontotemporal Dementia (FTD) pathogenesis: What molecular mechanisms determine whether a neuron develops tau pathology versus TDP-43 pathology?[1][2] This question is particularly critical because both GRN (progranulin) and MAPT (tau) mutations cause FTD, yet they result in fundamentally different proteinopathies[3].
The question of tau vs TDP-43 fate switching represents a critical crossroads in FTD pathogenesis:
Heterozygous GRN mutations cause FTD through progranulin haploinsufficiency, leading to TDP-43 proteinopathy[7][8]. Key molecular determinants include:
MAPT mutations directly cause tau pathology through[12]:
Classic neuropathology described FTLD-Tau and FTLD-TDP as mutually exclusive[16]. This suggests:
Recent studies have identified cases with mixed pathology[17][18]:
FTD shows characteristic patterns of regional involvement[20]:
| Region | Primary Pathology | Key Cell Types |
|---|---|---|
| Frontal cortex | Both tau and TDP-43 | Layer 2/3 pyramidal neurons |
| Temporal cortex | TDP-43 > tau | Von Economo neurons |
| Basal ganglia | TDP-43 | Medium spiny neurons |
| Brainstem | TDP-43 | Pigmented neurons |
Bott NT, et al. Frontotemporal dementia. Continuum. 2023. ↩︎
Rascovsky L, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011. ↩︎
Ghetti B, et al. Frontotemporal dementia caused by MAPT mutations: a detailed clinical and pathological account. Brain. 2023. ↩︎
Boxer AL, et al. New directions in clinical trials for frontotemporal dementia. Nat Rev Neurol. 2023. ↩︎
Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol. 2023. ↩︎
Van Mossevelde S, et al. Clinical phenotype of Belgian founder GRN mutation. Neurology. 2023. ↩︎
Baker M, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2023. ↩︎
Ward ME, et al. FTLD-TDP profiling: a new approach to understanding disease heterogeneity. Acta Neuropathol. 2024. ↩︎
Chang MC, et al. Progranulin deficiency leads to impaired lysosomal function. J Neurosci. 2023. ↩︎
Elia LP, et al. Progranulin deficiency modulates neuroinflammation in FTD. Brain. 2024. ↩︎
Liu Y, et al. Stress granule dynamics in progranulin-deficient neurons. Nat Neurosci. 2023. ↩︎
Guo W, et al. MAPT mutations and tau pathophysiology in FTD. Acta Neuropathol Commun. 2023. ↩︎
Hanger DP, et al. Tau phosphorylation in neurodegenerative diseases. Trends Neurosci. 2023. ↩︎
Kadavath H, et al. Tau microtubule binding in mutant tauopathies. Proc Natl Acad Sci. 2023. ↩︎
Wszolek ZK, et al. Tau isoform composition in MAPT mutation carriers. Neurology. 2023. ↩︎
Mackenzie IR, et al. Nomenclature and nosology for FTLD. Acta Neuropathol. 2023. ↩︎
Josephs KA, et al. FTLD-TDP with co-occurring tau pathology. Acta Neuropathol. 2024. ↩︎
Robinson JL, et al. Mixed pathologies in FTD. Brain. 2024. ↩︎
Cooper B, et al. C9orf72 expansion and mixed pathology in ALS-FTD. Acta Neuropathol. 2023. ↩︎
Seeley WW, et al. Neuroanatomical correlates of behavioral variant FTD. Brain. 2023. ↩︎
Gerrits E, et al. Single-cell analysis of tau and TDP-43 vulnerability. Cell. 2024. ↩︎
Baxi EG, et al. iPSC models of tau vs TDP-43 fate switching. Stem Cell Reports. 2024. ↩︎
Chia R, et al. Tau and TDP-43 protein interaction networks. Mol Neurodegener. 2024. ↩︎